---
title: "China Approves Bayer’s Nubeqa for Advanced Prostate Cancer Treatment"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274626496.md"
datetime: "2026-02-03T09:03:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274626496.md)
  - [en](https://longbridge.com/en/news/274626496.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274626496.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274626496.md) | [English](https://longbridge.com/en/news/274626496.md)


# China Approves Bayer’s Nubeqa for Advanced Prostate Cancer Treatment

Bayer AG has received its third regulatory approval in China for Nubeqa™ (darolutamide) for the treatment of men with advanced prostate cancer. The Chinese National Medical Products Administration (NMPA) approved the oral androgen receptor inhibitor (ARi) Nubeqa™ in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC). This approval is based on positive results from the Phase III ARANOTE trial, which demonstrated that darolutamide plus ADT significantly reduced the risk of radiological progression or death compared to placebo plus ADT. Darolutamide is now the first and only ARi approved in China for use in combination with ADT, with or without chemotherapy, for this patient group. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on February 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### 相關股票

- [Bayer AG (BAYN.DE)](https://longbridge.com/zh-HK/quote/BAYN.DE.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Bayer (BAYRY.US)](https://longbridge.com/zh-HK/quote/BAYRY.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md)

## 相關資訊與研究

- [Bayer - AskBio announces completion of enrollment in phase 2 clinical trial of AB-1002](https://longbridge.com/zh-HK/news/281314240.md)
- [UK Regulator OKs Bayer's Treatment for Advanced Non-small Cell Lung Cancer](https://longbridge.com/zh-HK/news/281501722.md)
- [Bayer rejigs marketing claims after advertising body challenge](https://longbridge.com/zh-HK/news/281525890.md)
- [Bayer Reaffirms Pharma Targets, Aiming for 30% Margin](https://longbridge.com/zh-HK/news/281359378.md)
- [Bayer Announces Approval Of New Indication For Kerendia In The EU](https://longbridge.com/zh-HK/news/280969658.md)